首页> 外文期刊>European journal of pharmaceutics and biopharmaceutics: official journal of Arbeitsgemeinschaft fuer Pharmazeutische Verfahrenstechnik e.V >Preparation of sustained release matrix pellets by melt agglomeration in the fluidized bed: influence of formulation variables and modelling of agglomerate growth.
【24h】

Preparation of sustained release matrix pellets by melt agglomeration in the fluidized bed: influence of formulation variables and modelling of agglomerate growth.

机译:在流化床中通过熔融团聚制备缓释基质药丸:配方变量和团聚体生长模型的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

The one-step preparation of sustained release matrix pellets, using a melting procedure in a fluidized bed apparatus, was tested in a 2(3) full factorial design of experiments, using microcrystalline wax as lipophilic binder, theophylline as model drug and talc as additional matrix forming agent. The three influence parameters were (A) size of binder particles, (B) fraction of theophylline in solid particles and (C) fraction of microcrystalline wax in formulation. The response variables were agglomerate size and size distribution, dissolution time, agglomerate crush resistance, sphericity, yield and porosity. Nearly spherical pellets comprising a smooth, closed surface could be obtained with the used method, exhibiting the hollow core typical for the immersion and layering mechanism. The reproducibility was very good concerning all responses. The size of agglomerates is proportional to the size of the binder particles, which serve as cores for pellet formation in the molten state in the fluidized bed. Additionally, the agglomerate size is influenced by the volume of the solid particles in relation to the binder particles, with more solid particles leading to larger agglomerates and vice versa. Dissolution times vary in a very wide range, resulting from the interplay between amount of drug in relation to the meltable matrix substance microcrystalline wax and the non-meltable matrix substance talc. The change of binder particle size does not lead to a structural change of the matrix; both dissolution times and porosity are not significantly altered. Agglomerate crush resistance is low due to the hollow core of the pellets. However, it is significantly increased if the volume fraction of microcrystalline wax in the matrix is high, which means that the matrix is mechanically better stabilized. A theoretical model has been established to quantitatively explain agglomerate growth and very good accordance of the full particle size distributions between predicted and actual values could be shown. A low volumetric binder to solids ratio is compensated by a more porous layer. On the basis of this model, in-depth understanding on the mechanism and influence of product properties could be gained; and an a priori estimation of particle size distributions for new formulas can be performed, with densities, formula, and binder particle size distribution as input parameters.
机译:在2(3)全因子设计的实验中,使用微晶蜡作为亲脂性粘合剂,以茶碱为模型药物,并以滑石粉作为补充剂,使用流化床设备中的熔融程序一步制备缓释基质药丸基质形成剂。这三个影响参数是:(A)粘合剂颗粒的大小,(B)茶碱在固体颗粒中的比例和(C)在制剂中微晶蜡的比例。响应变量是附聚物的大小和尺寸分布,溶解时间,附聚物的抗压性,球形度,产率和孔隙率。用所使用的方法可以获得具有光滑,封闭表面的近球形粒料,其具有典型的浸入和分层机制的空心。关于所有响应,重现性都很好。附聚物的尺寸与粘合剂颗粒的尺寸成比例,粘合剂颗粒用作流化床中熔融状态下颗粒形成的核心。另外,附聚物的尺寸受固体颗粒相对于粘合剂颗粒的体积的影响,其中更多的固体颗粒导致较大的附聚物,反之亦然。溶解时间在非常宽的范围内变化,这是由于相对于可熔融基质物质微晶蜡的药物量与不可熔融基质物质滑石之间的相互作用。粘合剂粒径的变化不会导致基体的结构变化。溶解时间和孔隙率都没有明显改变。由于粒料的空心,团聚物的抗压碎性低。但是,如果基体中微晶蜡的体积分数较高,则显着增加,这意味着基体在机械上具有更好的稳定性。已经建立了一个理论模型来定量解释团聚体的生长,并且可以很好地表明预测值和实际值之间的整个粒度分布。较低的粘合剂与固体的体积比可通过多孔性更高的层来补偿。在此模型的基础上,可以深入了解产品性能的机理和影响。并且可以将密度,配方和粘合剂的粒径分布作为输入参数,对新配方的粒径分布进行事前估算。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号